Future trends in the treatment of serious gram-positive infections

Drugs of Today

Volumn 45, Issue 1, 2009, Pages 47-54

  Metzger, Rosemarie ^a   Bonatti, Hugo ^a   Sawyer, Robert ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BACTERIAL VACCINE; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFTAROLINE FOSAMIL; CEFTOBIPROLE; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FOSFOMYCIN; FUSIDIC ACID; GARENOXACIN; LINEZOLID; MINOCYCLINE; ORITAVANCIN; PSEUDOMONIC ACID; RIFAMPICIN; STREPTOGRAMIN; TEICOPLANIN; TELAVANCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; XRP 2868;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIUM ISOLATION; BONE MARROW TOXICITY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DIPHTHERIA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCAL INFECTION; GASTROINTESTINAL TOXICITY; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEADACHE; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; IMMUNIZATION; INFECTION CONTROL; LACTIC ACIDOSIS; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYALGIA; MYOSITIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PHOTOTOXICITY; PREVALENCE; RASH; REVIEW; SKIN INFECTION; SLEEP DISORDER; SODIUM OVERLOAD; STAPHYLOCOCCUS INFECTION; STEVENS JOHNSON SYNDROME; STREPTOCOCCUS INFECTION; TASTE DISORDER; TETANUS;

EID: 63449108934     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Amyes, S.G. Enterococa and streptococci. Int J Antimicrob Agents 2007, 29(Suppl. 3): S43-52.
2. Witte, W., Cuny, C, Strommenger, B., Braulke, C, Heuck, D. Emergence of a new community acquired MRSA strain in Germany. Euro Surveill 2004, 9(1): 16-8.
3. Arya, B., Hussian, S., Hariharan, S. Rhodococcus equi pneumonia in a renal transplant patient: A case report and review of literature. Clin Transplant 2004,18(6): 748-52.
4. Bartlett, J.G. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008, 46(Suppl.l):S4-ll.
5. Lianou, A., Sofos, J.N. A review of the incidence and transmission of Listeria monocytogenes in ready-to-eat products in retail and food service environments. J Food Prot 2007, 70(9): 2172-98.
6. Rekha, A., Gopalan, T.R. Civilian gas gangrene: A clinical challenge. Int J Low Extrem Wounds 2007, 6(2): 98-101.
7. Vitek, C.R. Diphtheria Curr Top Microbiol Immunol 2006, 304: 71-94.
8. Ozkurt, Z., Parlak, M., Tastan, R., Dinler, U., Saglam, Y.S., Ozyurek, S.F. Anthrax in eastern Turkey, 1992-2004. Ernerg Infect Dis 2005,11(12): 1939-41.
9. Gentit, A., Soichot, P., Maugras, C. et al. [Botulism has not disappeared.] Presse Med 2008, 37(5 Pt. 1): 789-92.
10. Debue-Barazer, C. [Gas gangrene during World War I on the Western Front.] Ann Demogr Hist (Paris) 2002, 51-70.
11. Graham, R.C. Jr. Antibiotics for treatment of infections caused by Cram-positive cocci. Med Clin North Am 1974, 58(3): 505-17.
12. Zimmerman, R.K., Middleton, D.B., Bums, IT, Clover, R.D., Kimmel, S.R. Routine vaccines across the life span. 2007, J Fam Pract 2007; 56(2 Suppl. Vaccines): S18-37, Cl-3.
13. Herzer, CM. Toxic shock syndrome: Broadening the differential diagnosis. J Am Board Fam Pract 2001,14(2); 131-6.
14. Appelbaum, PC. MRSA - the tip of the iceberg. Clin Microbiol Infect 2006,12(Suppl. 2): 3-10.
15. Griffin, F.A. 5 Million Lives Campaign. Reducing methicillin- resistant Staphylococcus aureus (MRSA) infections. Jt Comm J Qual Patient Saf 2007, 33(12): 726-31.
16. von Eiff, C, Peters, G, Heilmann, C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis 2002, 2(11): 677-85.
17. Raz, R, Colodner, R., Kunin, CM. Who are you - Staphylococcus saprophyticus? Clin Infect Dis 2005, 40(6): 896-8.
18. Belko, J, Goldmann, D.A., Macone, A., Zaidi, A.K. Clinically significant infections with organisms of the Streptococcus milleri group. Pediatr Infect Dis J 2002, 21(8): 715-23.
19. Mitchell, T.J. The pathogenesis of streptococcal infections: From tooth detuy to meningitis. Nat Rev Microbiol 2003, 1(3): 219-30.
20. Werno, A.M., Murdoch, D.R. Medical microbiology: Laboratory diagnosis of invasive pneumococcal disease. Clin Infect Dis 2008, 46(6): 926-32.
21. Ostrowsky, B.E., Venkataraman, L, D'Agata, EM, Cold, H.S, DeGirolami, PC, Samore, M.H. Vancomycin-resistant enterococci in intensive care units: High frequency of stool carriage during a non-outbreak period. Arch Intern Med 1999,159(13): 1467-72.
22. Albright, J.B., Bonatti, H, Mendez, J. et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int 2007, 20(10): 856-66.
23. Slelzmueller, I, Goegele, H, Biebl, M. et al. Clostridium difficile colitis in solid organ transplantation - a single-center experience. Dig Dis Sci 2007, 52(11): 3231-6.
24. Stelzmueller, I, Wiesmayr, S., Eller, M. et al. Enterocolitis due to simultaneous infection with rotavirus and Clostridium difficile in adult and pediatric solid organ transplantation. J Gastrointest Surg 2007,11(7): 911-7.
25. Berger, N, Guggenbichter, S, Steurer, W. et al. Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants. BMC Infect Dis 2006, 6:127.
26. Berger, N, Wirmsberger, R, Kafka, R. et al. Infectious complications following 72 consecutive enteric-drained pancreas transplants. Transpl Int 2006,19(7): 549-57.
27. Bonatti, H, Steurer, W, Konigsralner, A, Allerberger, F, Margreiter, R. Infection of the pancreatic duct following pancreas transplantation with bladder drainage. J Chemother 1995, 7(5): 442-5.
28. Stelzmueller, I, Berger, N, Wiesmayr, S. et al. Croup milleri streptococci: Significant pathogens in solid organ recipients. Transpl Int 2007, 20(1): 51-6.
29. Stauffer, J. BH, Norman, K. Acid-blocking medication usage pre- and post-liver transplantation. Eursurg 2007, 39: 57.
30. Rice, L.B. Antimicrobial resistance in Cram-positive bacteria. Am J Infect Control 2006, 34: Sll-9.
31. Snyder, J.W., McDonald, L.C, Van Enk, R. Common bacteria whose susceptibility to antimicrobials is no longer predictable. J Med Liban 2000, 48(4): 208-14.
32. enichetti, F. Current and emerging serious Cram-positive infections. Clin Microbiol Infect 2005, ll(Suppl. 3): 22-8.
33. Johnson, A.P., Livermore, D.M., Tillotson, G.S. Antimicrobial susceptibility of Gram-positive bacteria: What's current, what's anticipated? J Hosp Infect 2001, 49(Suppl. A): 53-11.
34. Pankuch, C.A., Jacobs, M.R., Appelbaum, P.C. Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials. J Antimicrob Chemother 2003, 51(2): 443-6.
35. Pankuch, G.A., Kelly, L.M., Lin, G. et al. Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and Haemophilus species. Antimicrob Agents Chemother 2003, 47(10): 3270-4.
36. Van Bambeke, R, Reinert, R.R, Appelbaum, P.C, Tulkens, P.M., Peetermans, W.E. Multidrug-resistant Streptococcus pneumoniae infections: Current and future therapeutic options. Drugs 2007, 67(16): 2355-82.
37. Jones, R.N. Resistance patterns among nosocomial pathogens: Trends over the past few years. Chest 2001,119(2 SuppL): 397S-404S.
38. Kramer, A, Schwebke, I, Kampf, G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006, 6:130.
39. Bonten, M.J, Willems, R, Weinstein, R.A. Vancomycin- resistant enterococci: Why are they here, and where do they come from? Lancet Infect Dis 2001,1(5): 314-25.
40. Witte, W. Impact of antibiotic use in animal feeding on resistance of bacterial pathogens in humans. Ciba Found Symp 1997, 207: 61-71.
41. McKenna, M. The many faces of MRSA: Community- acquired infection knows no bounds. Ann Emerg Med 2008, 51(3): 285-8.
42. Cunha, B.A. A useful clinical approach to community- acquired methicillin-resistant Staphylococcus aureus (CA- MRSA) infections. J Hosp Infect 2008, 68(3): 271-3.
43. Llera, J.L., Levy, R.C, Staneck, J.L. Cutaneous abscesses: Natural history and management in an outpatient facility. J Emerg Med 1984,1(6): 489-93.
44. Hanage, W.P. Serotype-specific problems associated with pneumococcal conjugate vaccination. Future Microbiol 2008, 3(1): 23-30.
45. Bubeck Wardenburg, J, Schneewind, O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008, 205(2): 287-94.
46. Simor, A.E, Stuart, T.L, Louie, L. et al. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in
47. Canadian hospitals. Antimicrob Agents Chemother 2007, 51(11): 3880-6.
48. Perl, T.M., Cullen, J.J., Wenzel, R.P. et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002, 346(24): 1871-7.
49. Simor, A.E, Phillips, E, McCeer, A. et al. Randomized con\trolled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin- resistant Staphylococcus aureus colonization. Clin Infect Dis 2007, 44(2): 178-85.
50. Finkelstein, R, Rabino, G, Mashiah, T. et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002,123(2): 326-32.
51. Giamarellou. H. Treatment options for multidrug-resistant bacteria. Expert Rev Anti Infect Ther 2006, 4(4): 601-18.
52. Rybak, M.J, Hershberger, E, Moldovan, T, Grucz, R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000, 44(4): 1062-6.
53. Page, M.G. Anti-MRSA beta-lactams in development. Curr Opin Pharmacol 2006, 6(5): 480-5.
54. Livermore, D.M. Can beta-lactams be re-engineered to beat MRSA? Clin Microbiol Infect 2006,12(Suppl. 2): 11-6.
55. Noel, G.J. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007,13(Suppl. 2): 25-9.
56. Bush, K, Heep, M, Macielag, M.J, Noel, G.J. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: The first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007; 16(4): 419-29.
57. Tajima, Y. Polyoxotungstates reduce the beta-lactam resistance of methicillin-resistant Staphylococcus aureus. Mini Rev Med Chem 2005, 5(3): 255-68.
58. Guay, D.R. Oritavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 2004, 24(1): 58-68.
59. Vara Prasad, J.V. New oxazolidinones. Curr Opin Microbiol 2007,10(5): 454-60.
60. Appelbaum, P.C. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006,12(Suppl. 1): 16-23.
61. Tiwari, H.K., Sen, M.R. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 2006, 6:156.
62. Micek, ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007, 45(Suppl. 3): S184-90.
63. Szumowski, J.D., Cohen, D.E., Kanaya, F, Mayer, K.H. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007, 51(2): 423-8.
64. Martinez-Aguilar, G., Hammerman, W.A., Mason, E.O. Jr., Kaplan, S.L. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003, 22(7): 593-8.
65. Daum, R.S. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007, 357(4): 380-90.
66. Fiebelkorn, K.R., Crawford, S.A., McElmeel, M.L., Jorgensen, J.H. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 2003, 41(10): 4740-4.
67. Markowitz, N., Quinn, E.L., Saravolatz, L.D. Trimethoprim- sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992,117(5): 390-8.
68. Diekema, D.J., Pfaller, M.A., Schmitz, F.J. et al. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32(Suppl. 2): S114-32.
69. Ruhe, J.J., Menon, A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007, 51(9): 3298-303.
70. Drew, R.H. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 2007, 27(2): 227-49.
71. Howden, B.P., Grayson, M.L. Dumb and dumber - the potential waste of a useful antistaphylococcal agent: Emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006, 42(3): 394-400.
72. Pan, A., Lorenzotti, S., Zoncada, A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Patents Anti-lnfect Drug Disc 2008, 3(1): 10-33.
73. Shrestha, N.K., Chua, J.D., Tuohy, M.J. et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: Potential utility of fosfomycin. Scand J Infect Dis 2003, 35(1): 12-4.
74. Falagas, M.E., Kopterides, P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 2007; 13(5): 592-7.
75. Allerberger, F., Klare, I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999, 43(2): 211-7.
76. Grif, K., Dierich, M.P., Pfaller, K, Miglioli, P.A., Allerberger, F. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother. 2001; 48: 209-17
77. Brogden, R.N., Peters, D.H. Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994, 47(5): 823-54.
78. Weinbren, M., Struthers, K. Emergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapy. J Antimicrob Chemother 2002, 50(2): 306-7.
79. Johnson, A.P., Utttey, A.H., Woodfoid, N., George, R.C. Resistance to vancomycin and teicoplanin: An emerging clinical problem. Clin Microbiol Rev 1990, 3(3): 280-91.
80. Pea, F., Brollo, L, Viale, P., Pavan, R, Furlanut, M. Teicoplanin therapeutic drug monitoring in critically ill patients: A retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 2003, 51(4): 971-5.
81. Paterson, D.L. Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 2006, 6(5): 486-90.
82. Jones, R.N., Ballow, C.H., Biedenbach, D.J., Deinhart, J.A., Schentag, J.J. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol infect Dis 1998, 31(31): 437-51.
83. Drew, R.H., Perfect, J.R., Srinath, L, Kurkimilis, E., Dowzicky, M., Talbot, G.H. For the Synercid Emergency-Use Study Group. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin- dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2000, 46(5): 775-84.
84. Weigelt, J, Itani, K., Stevens, D., Lau, W., Dryden, M., Knirsch, C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005, 49(6): 2260-6.
85. Wunderink, R.C., Rello, J., Cammarata, S.K., Croos- Dabrera, R.V., Kollef, M.H. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003,124(5): 1789-97.
86. Patanwala, A.E., Erstad, B.L., Nix, D.E. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Curr Med Res Opin 2007, 23(1): 185-93.
87. McCollum, M., Rhew, D.C., Parodi, S. Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species. Clin Ther2003, 25(12): 3173-89.
88. Pfaller, M.A., Sader, H.S., Jones, R.N. Evaluation of the in vitro activity of daptomycin against 19,615 clinical isolates of Cram- positive cocci collected in North American hospitals (2002- 2005). Diagn Microbiol Infect Dis 2007, 57(4): 459-65.
89. Van Bambeke, F. Clycopeptides in clinical development: Pharmacological profile and clinical perspectives. Curr Opin Pharmacol 2004, 4(5): 471-8.
90. Arbeit, R.D., Maki, D., Tally, F.P., Campanaro, E., Eisenstein. R.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 20 04, 38(12): 1673-81.
91. Fowler, V.G. Jr., Boucher, H.W., Corey, C.R. et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355(7): 653-65.
92. Silverman, J.A., Mortin, L.I., Vanpraagh, A.D., Li, T., Alder, J. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis 2005, 191(12): 2149-52.
93. Ziglam, H. Daptomycin and tigecycline: A review of clinical efficacy in the antimicrobial era. Expert Opin Pharmacother 2007, 8(14): 2279-92.
94. Streit, J.M., Fritsche,T.R., Sader, H.S., Jones, R.N. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004, 48(2): 137-43.
95. Jauregui, L.E., Babazadeh, S., Seltzer, E. et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005, 41(10): 1407-15.
96. Stryjewski, M.E., Chu, V.H., O'Riordan, W.D. et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006, 50(3): 862-7.
97. Loutit, J. Mode of action and current status of the glycopeptide oritavancin. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst 617.
98. Poulakou, C, Giamarellou, H. Oritavancin: A new promising agent in the treatment of infections due to Gram-positive pathogens. Expert Opin Investig Drugs 2008, 17(2): 225-243.
99. Ellis-Grosse, E.J., Babinchak, T., Dartois, N., Rose, G., Loh, E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl. 5): S341-53.
100. Babinchak, T., Ellis-Grosse, E., Dartois, N., Rose, G.M., Loh, E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 2005,41(Suppt. 5): S354-67.
101. lOO. Novielto, S., lanniello, R, Leone, S., Esposito, S. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. J Antimicrob Chemother 2003, 52(5): 869-72.
102. Hayakawa, I. [The possibility of drug design of quinolones effective for multiresistant Gram-positive pathogens.] Nippon Rinsho 1997, 55(5): 1266-71.
103. Shetty, N., Wilson, A.P. Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2000, 46(4): 633-8.
104. Dupuis, M., Leclercq, R. Activity of a new oral streptogramin, XRP2868, against Gram-positive cocci harboring various mechanisms of resistance to streptogramins. Antimicrob Agents Chemother 2006, 50(1): 237-42.
105. Goldstein, E.J., Citron, D.M., Merriam, C.V. et al. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin- dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic Gram-positive species, actinomycetes, and lactobacilli. Antimicrob Agents Chemother 2005, 49(1): 408-13.
106. Jacqueline, C, Caillon, J., Le Mabecque, V. et at. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007, 51(9): 3397-400.
107. Koyama, N., Nagahiro, T., Yamaguchi, Y., Masuma, R., Tomoda, H., Omura, S. Stemphones, novel potentiators of imipenem activity against methicillin-resistant staphylococcus aureus, produced by Aspergillus sp. FKI-2136. J Antibiot (Tokyo) 2005, 58(11): 695-703.
108. Tajima, Y. Effects of tungstosilicate on strains of methicillin- resistant Staphylococcus aureus with unique resistant mechanisms. Microbiol Immunol 2003, 47(3): 207-12.
109. 108.Dittmann, S., Wharton, M., Vitek, C. et al. Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: Lessons learned. J Infect Dis 2000,181(Suppl.l): S10-22.